1. Scrip
  2. >>R&D
  3. >>Clinical Trials

What GSK’s Depemokimab Will Have To Show In Chronic Rhinosinusitis

 
• By Elizabeth Cairns

Until the full data are released, it is difficult to weigh ANCHOR.

nose
• Source: Alamy

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a minor indication for GSK’s depemokimab compared with its commercial potential in asthma. Nonetheless, the market is worth contesting, and the topline Phase III hit the UK group disclosed on 14 October could enable it to carve out share from occupants including Dupixent.

Key Takeaways
  • GSK’s anti-IL-5 antibody depemokimab has succeeded in the twin ANCHOR-1 and -2 studies in chronic rhinosinusitis with nasal polyps, though only the topline hit has been revealed so far.

However, depemokimab has itself set an uneasy precedent. Its pivotal asthma trial was revealed as a success in May, but...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Clinical Trials

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

IO Biotech Plans Cylembio Filing Despite ‘Narrowly Missed’ Phase III Endpoint

 
• By Mandy Jackson

The company plans to meet with the US FDA prior to submitting a BLA before the end of 2025 for its cancer vaccine as a first-line advanced melanoma treatment in combination with Keytruda.

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 
• By Alexandra Shimmings

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.

More from Therapy Areas

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 
• By Alaric DeArment

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.

Sanofi’s Sarclisa Wins Another EU Multiple Myeloma Nod In Its Unequal Battle With J&J’s Darzalex

 
• By Sushmita Panda

The French drugmaker's anti-CD38 antibody has racked up another approval in first-line multiple myeloma, but it marks a small victory while the company develops a subcutaneous version to help level the field with J&J’s Darzalex.

Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted

 
• By Jessica Merrill

The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.